A Phase 3 interventional study of Aspirin 81mg and Aspirin 162 mg in Pulmonary Disease, Chronic Obstructive, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Johns Hopkins University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University — 4 open to participants now, 4 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Johns Hopkins University.
Among the 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University, this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 3, and was the 20th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →4 of the 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 40+
Johns Hopkins University · Sites in United States
Ages 40+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 89 across the 19 interventional studies, 199 across the 4 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
3 of the studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05297279Johns Hopkins UniversityOMEGA - Dietary Intervention - COPD Trial | 2027-03 |
| NCT07686302Johns Hopkins UniversityFeasibility of Noninvasive Trigeminal Nerve Stimulation During Exercise | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Pulmonary Disease, Chronic Obstructive by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Current treatments for COPD focus on inhaler therapies that do not address manifestations of the disease on other organ systems. Platelets, which are small blood cells that typically help with clotting, are also involved in generalized inflammation and dysfunctionality of immune cells when these cells become activated. Activated platelets have long been known to play a role in the development of cardiovascular disease. However, there is recent evidence that activated platelets may be involved in worse respiratory symptoms in COPD independent of cardiovascular disease. Individuals with COPD who are taking aspirin, which is an antiplatelet agent that blocks activation of platelets, have been shown to have improved respiratory symptoms, fewer COPD flares, and lower mortality. The investigators' ultimate goal is to study whether aspirin use improves respiratory symptoms independent of cardiovascular disease. The investigators are conducting the current pilot trial to determine the optimal dose of aspirin that blocks platelet activation in this population and investigate whether there are any blood or urine tests that can help with understanding response to therapy. The results will inform the design of a larger trial investigating clinical outcomes. The investigators hypothesize that daily low-dose aspirin will not be sufficient to adequately suppress platelet activation and that an aspirin dose of at least 162mg daily will be necessary.
The trial will enroll individuals with chronic obstructive pulmonary disease (COPD). The primary design will be a randomized double-blind 6-sequence, 3-period, 3-treatment sequential crossover trial for which the investigators will randomize participants to receive 81mg, 162mg, and 325mg aspirin in one of six pre-specified sequences with a 14-day washout period between doses. Participants will have three follow-up visits after randomization.
Individuals who agree to participate in the clinical trial will be randomized to one of six treatment sequences using a computer algorithm at the baseline study visit. Study drug will be provided by the Johns Hopkins Research Pharmacy and participants instructed to take one pill once per day at the same time. All study drug doses will be compounded to appear identical and placed in identical containers fitted with an electronic cap for monitoring medication adherence. Participants will be scheduled to return for a follow-up visit at two weeks, six weeks, and ten weeks after randomization. Blood and urine samples will be collected at each visit. Data will be collected by the principal investigator or trained study coordinator and will be electronically entered into a database stored on the secure Johns Hopkins servers through an online interface that is password protected. Urine will be collected and analyzed for 11-dehydro-thromboxane B2 at each study visit and constitutes the primary outcome of the study. Secondary outcomes will include measurement of platelet reactivity to U46619, a thromboxane A2 agonist, through identification of platelet surface markers CD62P, CD63, CD154 and PAC1.
The following adherence measurements will also be collected:
The following clinical data will be collected at randomization:
1. Spirometry performed before and after administration of albuterol per American Thoracic Society protocol in a certified laboratory
The following clinical data will be collected at randomization and each subsequent study visit:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Week 1-2: aspirin 81mg * Week 5-6: aspirin 162mg * Week 9-10: aspirin 325mg
Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg
* Week 1-2: aspirin 162mg * Week 5-6: aspirin 81mg * Week 9-10: aspirin 325mg
Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg
* Week 1-2: aspirin 325mg * Week 5-6: aspirin 81mg * Week 9-10: aspirin 162mg
Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg
* Week 1-2: aspirin 325mg * Week 5-6: aspirin 162mg * Week 9-10: aspirin 81mg
Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg
* Week 1-2: aspirin 162mg * Week 5-6: aspirin 325mg * Week 9-10: aspirin 81mg
Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg
* Week 1-2: aspirin 81mg * Week 5-6: aspirin 325mg * Week 9-10: aspirin 162mg
Drug: Aspirin 81mg · Drug: Aspirin 162 mg · Drug: Aspirin 325mg
Aspirin 81mg once daily
Also known as: Acetylsalicylic acid
Aspirin 162 mg once daily
Also known as: Acetylsalicylic acid
Aspirin 325mg once daily
Also known as: Acetylsalicylic acid
Change in urinary 11-dehydro-thromboxane B2 level
Urine 11-dehydro-thromboxane B2 level (pg/mg Creatinine) - a urinary metabolite of thromboxane A2.
Time frame: Baseline, week 2, week 6, week 10
Change in serum thromboxane B2 level
Serum thromboxane B2
Time frame: Baseline, week 2, week 6, week 10
Change in proportion of platelets displaying CD62P
Proportion of platelets displaying CD62P (activated platelets) following stimulation with U46619, a thromboxane A2 agonist.
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Change in proportion of platelets displaying CD63
Proportion of platelets displaying CD63 (activated platelets) following stimulation with U46619, a thromboxane A2 agonist.
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Change in proportion of platelets displaying CD154
Proportion of platelets displaying CD154 (activated platelets) following stimulation with U46619, a thromboxane A2 agonist
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Change in proportion of platelets displaying PAC1
Proportion of platelets displaying PAC1 (activated platelets) following stimulation with U46619, a thromboxane A2 agonist
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.
Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 43 months is close to that.
Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin
Pulmonary Disease, Chronic Obstructive →